Pladys Adélaïde, Bayat Sahar, Kolko Anne, Béchade Clémence, Couchoud Cécile, Vigneau Cécile
EHESP Rennes, Sorbonne Paris Cité, Rennes, France.
Université Rennes 1, UMR CNRS 6290, Rennes, France.
BMC Nephrol. 2016 Jul 29;17(1):107. doi: 10.1186/s12882-016-0306-7.
Increasing the weekly frequency of hemodialysis sessions has positive effects, on the control of several biological data of patients. However, knowledge about Daily HemoDialysis (DHD) practices is limited in France. The aim of the present study was to describe the characteristics and treatment trajectories of all French patients undergoing DHD.
All patients older than 18 years who started DHD between 2003 and 2012 in France were included and followed until December 31, 2013. The patients' demographic and clinical characteristics and treatment modalities were extracted from the French Renal Epidemiological and Information Network (REIN) registry.
During the inclusion period, 753 patients started DHD in France. Based on their median age (64 years), patients were classified in two groups: "old" group (≥64 years) and "young" group (<64 years). Patients in the old group had more comorbidities than in the young group: 48 % had diabetes (vs 29 % in the young group), 17 % an active malignancy (vs 10 %) and 80 % ≥1 cardiovascular disease (vs 41 %). Concerning patients' treatment trajectories, 496 (66 %) patients started with another dialysis before switching to DHD and 257 (34 %) directly with DHD. At the end of the follow-up, 69 % of patients in the old group were dead (27.4 % in the young group) and kidney transplantation was more frequent in the young group (30.4 % vs 0.5 %).
In France, DHD is proposed not only to young in rather good clinical conditions and waiting for kidney transplantation, but also to old and frail patients with higher mortality.
增加血液透析治疗的每周频率对控制患者的多项生物学指标具有积极作用。然而,在法国,关于每日血液透析(DHD)实践的了解有限。本研究的目的是描述所有接受DHD治疗的法国患者的特征和治疗轨迹。
纳入2003年至2012年期间在法国开始接受DHD治疗且年龄大于18岁的所有患者,并随访至2013年12月31日。从法国肾脏流行病学和信息网络(REIN)登记处提取患者的人口统计学和临床特征以及治疗方式。
在纳入期间,法国有753例患者开始接受DHD治疗。根据患者的中位年龄(64岁),将其分为两组:“老年”组(≥64岁)和“年轻”组(<64岁)。老年组患者的合并症比年轻组更多:48%患有糖尿病(年轻组为29%),17%患有活动性恶性肿瘤(年轻组为10%),80%患有≥1种心血管疾病(年轻组为41%)。关于患者的治疗轨迹,496例(66%)患者在转为DHD治疗前曾接受过其他透析治疗,257例(34%)患者直接开始接受DHD治疗。随访结束时,老年组69%的患者死亡(年轻组为27.4%),年轻组肾移植的发生率更高(30.4%对0.5%)。
在法国,DHD不仅适用于临床状况较好且等待肾移植的年轻患者,也适用于死亡率较高的老年体弱患者。